Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Safe transition to surgery: working differently to make blood transfusion process safer for elective surgery
Badjie, Karafa S., Rogers, James C., Jenkins, Sarah M. , Bundy, Kevin L., Stubbs, James R. , Badjie, Karafa S W, Rogers, James C., Cima, Robert R.

Mayo Clinic

Transfusion | April 9, 2015 | Volume: 55 | Issue: 9 | Pages: 2238-2245

10.1111/trf.13108 | PMID 25854123 Get It

BACKGROUNDOur institutional policy allows patients who are scheduled for elective surgery with no history of a pregnancy or blood transfusion in the preceding 3 months to have a presurgical sample (PSS) collected and tested up to 56 days before their scheduled surgery; however, our PSS TS completion rate in eligible patients before the morning of surgery was 83%. In 2011, a team was charged to develop a standardized process along with other process improvements while ensuring no increase in transfusion‐related events.STUDY DESIGN AND METHODSThe team followed the DMAIC framework in appraising the effectiveness and efficiency of the current state process including baseline data collection such as PSS TS completion rate, number of eligible patients needing a PSS TS on the day of surgery, benchmarking, SSBO utilization, and future state mapping.RESULTSFirst quarter (Q1) 2011 versus Q1 2012 postimplementation results showed significant improvements of the process including a 53% decrease in PSS TS on the day of surgery; a 13% increase in PSS TS completion before the morning of surgery; a 26% reduction in total XM RBCs; and a 58.8% reduction in XM RBCs not issued, plus a 47% decrease in RBC wastage. Q1 2011 versus Q1 2013 showed a 41% reduction in total XM RBCs and an 88.4% reduction in XM RBCs not issued but overall RBCs issued versus returned increased slightly and represents a future opportunity for improvement.CONCLUSIONSThe redesigned, transformational process eliminated SSBO and improved ordering process and PSS TS completion rate as well as blood product ordering and utilization.
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci
Olama, Ali Amin Al , Benlloch, Sara, Antoniou, Antonis C. , Giles, Graham G. , Severi, Gianluca , Neal, David E. , Hamdy, Freddie C. , Donovan, Jenny , Muir, Kenneth , Schleutker, Johanna , Henderson, Brian E., Haiman, Christopher A. , Schumacher, Fredrick R. , Pashayan, Nora , Ostrander, Elaine A. , Stanford, Janet L. , Batra, Jyotsna , Clements, Judith A. , Chambers, Suzanne K. , Weischer, Maren , Nordestgaard, Børge G. , Sørensen, Karina D. , Ørntoft, Torben F., Maier, Christiane, Doerk, Thilo, Dickinson, Joanne L. , Cannon‐Albright, Lisa , Brenner, Hermann , Habuchi, Tomonori , Thibodeau, Stephen N. , Cooney, Kathleen A. , Chappuis, Pierre O. , Hutter, Pierre, Kaneva, Radka , Foulkes, William D. , Lu, Yong‐Jie , Zhang, Hongwei , Stephenson, Robert A., Cox, Angela , Southey, Melissa C. , FitzGerald, Liesel M. , Leongamornlert, Daniel , Saunders, Edward J. , Tymrakiewicz, Malgorzata, Guy, Michelle, Little, Sarah J., Govindasami, Koveela, Sawyer, Emma, Wilkinson, Rosemary, Herkommer, Kathleen , Hopper, John L. , Lophatonanon, Aritaya, Rinckleb, Antje E., Eeles, Rosalind A. , Easton, Douglas F. , Dörk, Thilo , Aitken, Joanne F. , Borre, Michael , Lose, Felicity , Srinivasan, Srilakshmi , Tilley, Wayne D. , Samaratunga, Hemamali , Goranova, Teodora , Catto, James W.F. , Pharoah, Paul D.P. , Ingles, Sue A. , Park, Jong Y. , Cybulski, Cezary , Rebbeck, Timothy R. , Zeigler-Johnson, Charnita M , Zeegers, Maurice Petrus , Spurdle, Amanda B. , Dadaev, Tokhir , Kote‐Jarai, Zsofia , Dwyer, Terry , Dörk, Thilo , Giles, Graham G , Foulkes, William D , Eeles, Rosalind A , Southey, Melissa C , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Pashayan, Nora , Cannon-Albright, Lisa A , Brenner, Hermann , Cox, Angela , Samaratunga, Hemamali , Severi, Gianluca , Batra, Jyotsna , Clements, Judith

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 3, 2015 | Volume: 24 | Issue: 7 | Pages: 1121-1129

10.1158/1055-9965.epi-14-0317 | PMID 25837820 Get It

Abstract Background: Genome-wide association studies have identified multiple genetic variants associated with prostate cancer risk which explain a substantial proportion of familial relative risk. These variants can be used to stratify individuals by their risk of prostate cancer. Methods: We genotyped 25 prostate cancer susceptibility loci in 40,414 individuals and derived a polygenic risk score (PRS). We estimated empirical odds ratios (OR) for prostate cancer associated with different risk strata defined by PRS and derived age-specific absolute risks of developing prostate cancer by PRS stratum and family history. Results: The prostate cancer risk for men in the top 1% of the PRS distribution was 30.6 (95% CI, 16.4–57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI, 3.2–5.5) fold compared with the median risk. The absolute risk of prostate cancer by age of 85 years was 65.8% for a man with family history in the top 1% of the PRS distribution, compared with 3.7% for a man in the bottom 1%. The PRS was only weakly correlated with serum PSA level (correlation = 0.09). Conclusions: Risk profiling can identify men at substantially increased or reduced risk of prostate cancer. The effect size, measured by OR per unit PRS, was higher in men at younger ages and in men with family history of prostate cancer. Incorporating additional newly identified loci into a PRS should improve the predictive value of risk profiles. Impact: We demonstrate that the risk profiling based on SNPs can identify men at substantially increased or reduced risk that could have useful implications for targeted prevention and screening programs. Cancer Epidemiol Biomarkers Prev; 24(7); 1121–9. ©2015 AACR.
Analysis of muscle fiber clustering in the diaphragm muscle of sarcopenic mice
Greising, Sarah M. , Medina-Martínez, Juan S. , Vasdev, Amrit K., Sieck, Gary C. , Mantilla, Carlos B. , Sieck, Gary , Mantilla, Carlos B

Mayo Clinic

Muscle & Nerve | March 24, 2015 | Volume: 52 | Issue: 1 | Pages: 76-82

10.1002/mus.24641 | PMID 25808550 Get It

Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma
Psutka, Sarah P. , Leibovich, Bradley C. , Psutka, Sarah P

Mayo Clinic

Therapeutic Advances in Urology | March 18, 2015 | Volume: 7 | Issue: 4 | Pages: 216-229

10.1177/1756287215576443 | PMID 26445601 Get It

The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10% of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.
Dermatopathologists' concerns and challenges with clinical information in the skin biopsy requisition form: a mixed‐methods study
Comfere, Nneka I. , Peters, Margot S. , Jenkins, Sarah M. , Lackore, Kandace A. , Yost, Kathleen J. , Tilburt, Jon C. , Lackore, Kandace, Yost, Kathleen

Mayo Clinic

Journal of Cutaneous Pathology | March 10, 2015 | Volume: 42 | Issue: 5 | Pages: 333-345

10.1111/cup.12485 | PMID 25757028 Get It

BackgroundCommunication failures between clinicians and dermatopathologists are prevalent. Our primary objective was to characterize the concerns and challenges of dermatopathologists posed by incomplete or inaccurate clinical information in the skin biopsy requisition form.MethodsAn explanatory sequential, mixed‐methods study design comprised of a survey sent to 1103 members of the American Society of Dermatopathology (ASDP), followed by two focus group sessions.ResultsA total of 54% (598/1103) of dermatopathologists completed the questionnaire. Most dermatopathologists (80%; 436/548) viewed their roles to be providers of histopathological diagnosis and a report that is clinically meaningful. Paper or electronic requisition forms were the most common communication method (85%; 458/541) and were associated with the highest rates of dissatisfaction in 36% (193/537) of respondents. Inadequacy of specimens emerged as an important factor influencing judgment of the quality of provided clinical information. 44.7% (261/584) of dermatopathologists spent 30 minutes or more on average every day searching for relevant clinical information to assist with their histopathologic interpretation.ConclusionASDP dermatopathologists expressed significant dissatisfaction with the quality of clinical information in the requisition form and the time spent gathering information necessary for accurate, timely and clinically meaningful diagnosis. These findings have implications for the quality, safety and efficiency of dermatologic care.
Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk
Rhodes, Deborah J. , Breitkopf, Carmen Radecki , Jenkins, Sarah M. , Vachon, Celine M. , Radecki Breitkopf, Carmen, Ziegenfuss, Jeanette Y. , Vachon, Celine M.

Mayo Clinic

Journal of Clinical Oncology | March 3, 2015 | Volume: 33 | Issue: 10 | Pages: 1143-1150

10.1200/jco.2014.57.0325 | PMID 25732156 Get It

Purpose Legislation mandating disclosure of breast density (BD) information has passed in 21 states; however, actual awareness of BD and knowledge of its impact on breast cancer detection and risk are unknown. Methods We conducted a national cross-sectional survey administered in English and Spanish using a probability-based sample of screening-age women, with oversampling of Connecticut, the only state with BD legislation in effect for > 1 year before the survey. Results Of 2,311 women surveyed, 65% responded. Overall, 58% of women had heard of BD, 49% knew that BD affects breast cancer detection, and 53% knew that BD affects cancer risk. After multivariable adjustment, increased BD awareness was associated with white non-Hispanic race/ethnicity (Hispanic v white non-Hispanic: odds ratio [OR], 0.23; P < .001), household income (OR, 1.07 per category increase; P < .001), education (OR, 1.19 per category increase; P < .001), diagnostic evaluation after a mammogram (OR, 2.64; P < .001), and postmenopausal hormone therapy (OR, 1.69; P = .002). Knowledge of the masking effect of BD was associated with higher household income (OR, 1.10; P < .001), education (OR, 1.22; P = .01), prior breast biopsy (OR, 2.16; P < .001), and residing in Connecticut (Connecticut v other states: OR, 3.82; P = .003). Connecticut residents were also more likely to have discussed their BD with a health care provider (67% v 43% for residents of other US states; P = .001). Conclusion Disparities in BD awareness and knowledge exist by race/ethnicity, education, and income. BD legislation seems to be effective in increasing knowledge of BD impact on breast cancer detection. These findings support continued and targeted efforts to improve BD awareness and knowledge among women eligible for screening mammography.
Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
Strozzi, Isabella, Nolan, Sarah J, Sperling, Michael R. , Wingerchuk, Dean M. , Sirven, Joseph I , Nolan, Sarah J, Sperling, Michael R

Mayo Clinic

Cochrane Database of Systematic Reviews | February 12, 2015 | Volume: 2015 | Issue: 4 | Pages: No page available

10.1002/14651858.cd001902.pub2 | PMID 25922863 Get It

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Shapiro, Geoffrey I. , Bell‐McGuinn, Katherine M., Molina, Julian R. , Bendell, Johanna C. , Spicer, James , Kwak, Eunice L., Pandya, Susan , Millham, Robert, Borzillo, Gary , Pierce, Kristen J. , Han, Lixin, Houk, Brett E. , Gallo, Jorge D. , Alsina, María , Braña, Irene , Tabernero, Josep , Tabernero, Josep , Shapiro, Geoffrey I

Mayo Clinic

Clinical Cancer Research | February 4, 2015 | Volume: 21 | Issue: 8 | Pages: 1888-1895

10.1158/1078-0432.ccr-14-1306 | PMID 25652454 Get It

Abstract Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. Experimental Design: Part 1 of this open-label phase I study was designed to estimate the maximum-tolerated dose (MTD) in patients with nonselected solid tumors, using a modified continual reassessment method to guide dose escalation. Objectives of part 2 were MTD confirmation and assessment of preliminary activity in patients with selected tumor types and PI3K pathway dysregulation. Results: Seventy-seven of the 78 enrolled patients received treatment. The MTD for PF-05212384, administered intravenously once weekly, was estimated to be 154 mg. The most common treatment-related adverse events (AE) were mucosal inflammation/stomatitis (58.4%), nausea (42.9%), hyperglycemia (26%), decreased appetite (24.7%), fatigue (24.7%), and vomiting (24.7%). The majority of patients treated at the MTD experienced only grade 1 treatment-related AEs. Grade 3 treatment-related AEs occurred in 23.8% of patients at the MTD. No treatment-related grade 4–5 AEs were reported at any dose level. Antitumor activity was noted in this heavily pretreated patient population, with two partial responses (PR) and an unconfirmed PR. Eight patients had long-lasting stable disease (&gt;6 months). Pharmacokinetic analyses showed a biphasic concentration–time profile for PF-05212384 (half-life, 30–37 hours after multiple dosing). PF-05212384 inhibited downstream effectors of the PI3K pathway in paired tumor biopsies. Conclusions: These findings demonstrate the manageable safety profile and antitumor activity of the PI3K/mTOR inhibitor PF-05212384, supporting further clinical development for patients with advanced solid malignancies. Clin Cancer Res; 21(8); 1888–95. ©2015 AACR.